Antonio Fojo, MD
Enriched profileProfessor of Medicine; Co-Director, Adrenal Center · Columbia University Irving Medical Center
Antonio Fojo is Professor of Medicine; Co-Director, Adrenal Center at Columbia University Irving Medical Center. ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 2 Sept 2026
Antonio Fojo, M.D., PH.D., is Professor of Medicine at Columbia University Irving Medical Center / Vagelos College of Physicians and Surgeons (Herbert Irving Comprehensive Cancer Center). The public record shows 245 publications with 18,071 citations (h-index 55), centered on Adrenal Cortex Neoplasms, Glioma, Neuro-Oncology / Glioma. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 10 companies, 1 NIH-funded awards (2020–2024).
- Top research focus: Adrenal Cortex Neoplasms
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 2 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 2 Sept 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)
Sponsor: Antonio Fojo
- Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Sponsor: Columbia University
- Ponatinib in Advanced or Metastatic Medullary Thyroid Cancer
Sponsor: Antonio Fojo
Industry payments
Updated 2 Sept 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- SUN PHARMACEUTICAL INDUSTRIES INC.Program year20251 payment
- Daiichi Sankyo Inc.Program year20243 payments
- E.R. Squibb & Sons, L.L.C.Program year20233 payments
Medicare prescribing footprint (2020)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
100%Serotonin-3 Receptor Antagonist100%Ondansetron Odt100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 2 Sept 2026
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- PARP inhibitors: A review of the pharmacology, pharmacokinetics, and pharmacogenetics
Seminars in Oncology
2023 - Cancer medicines on the WHO Model List of Essential Medicines: processes, challenges, and a way forward
The Lancet Global Health
2022 - Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics
Clinical Cancer Research
2020 - Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models
Clinical Cancer Research
2019
Online presence
Updated 2 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/antonio-fojo-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/antonio-fojo-a071331a0
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Antonio-Fojo
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Mentions by others
where others cite or feature them- Other
who.int/about/people/biography/antonio-fojo
- YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 2 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vagelos.columbia.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vagelos.columbia.edu ↗
- Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗ - Board Certified
Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.columbia.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com ↗
- Editor at Large
The Oncologist
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →academic.oup.com ↗ - Editor
Seminars in Oncology
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →sciencedirect.com ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →vagelos.columbia.edu ↗
Media & interviews
press, podcasts and appearances- Interviewed by Kibur Medical (Kibur Science Spotlight) on challenges in cancer drug development
preclinical models, and the role of AI
2023verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →kiburmed.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Stanley Fahn, MD
Columbia University Irving Medical Center
Rebecca Hahn, MD
Columbia University Irving Medical Center
Susheel Kodali, MD
Columbia University Irving Medical Center
Ronald Wapner, MD
Columbia University Irving Medical Center